Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is positioned to be a leader in the multi-cancer early detection market with its innovative and comprehensive Galleri blood test, which has demonstrated strong growth in sales and test volume. The upcoming ASCO presentation and potential FDA approval and Medicare reimbursement will be key upcoming catalysts for the company's success. However, there are potential risks, including FDA approval delays or limitations, lack of Medicare reimbursement, and a slowdown in the self-pay market. Further risks to the medical and life science tools sector as a whole, such as reduced research and development budgets and government funding, may also impact GRAIL's success.

Bears say

GRAIL is currently facing challenges such as continued discounting and lower financial forecasts, and there is a significant downside risk if FDA approval for their Galleri test is not granted or Medicare does not provide coverage. However, there is also potential for positive catalysts, such as a positive ASCO data presentation and FDA approval, which could support the company's favorable view on the multi-cancer early detection (MCED) opportunity. Despite an attractive risk/reward profile, the impact of these challenges on the stock's performance outweighs the potential positive catalysts, leading to a negative outlook for GRAIL's stock performance.

GRAIL Inc (GRAL) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 7 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.